Kinetic and equilibrium studies of doxorubicin adsorption on MCM-41-type silica surface

N. V. Roik; L. A. Belyakova; M. O. Dziazko

doi:10.15407/hftp07.04.405

Authors

N. V. Roik Chuiko Institute of Surface Chemistry of National Academy of Sciences of Ukraine
L. A. Belyakova Chuiko Institute of Surface Chemistry of National Academy of Sciences of Ukraine
M. O. Dziazko Chuiko Institute of Surface Chemistry of National Academy of Sciences of Ukraine

DOI:

https://doi.org/10.15407/hftp07.04.405

Keywords:

MCM-41-type silica, doxorubicin, adsorption

Abstract

Doxorubicin belongs to the most widely used anticancer chemotherapy drugs. Yet the long?term treatment with doxorubicin is associated with toxic side effects. Minimization of undesired damages of healthy cells without reducing therapeutic action of doxorubicin can be attained using drug carrier systems, particularly silica nanoparticles. The aim of this work was elucidation of the probable mechanism of interaction between doxorubicin and silica surface. The adsorption of antitumor drug on mesoporous silica nanoparticles of MCM-41-type was studied depending on the contact time, pH of phosphate buffer solution, and doxorubicin concentration by use of UV-Vis spectroscopy. Experimental kinetic curves of adsorption were compared with theoretical models of Lagergren and Ho-McKay for pseudo-first and pseudo-second order processes. High correlation coefficients indicate that the kinetics of drug adsorption on silica surface at pH 5.0 and 7.0 can be fitted by pseudo-second order kinetic model. Equilibrium adsorption of doxorubicin was analyzed by Langmuir, Freundlich, Redlich?Peterson, and Brunauer?Emmet?Teller isotherm models. BET model is the most appropriate for prediction of doxorubicin equilibrium adsorption on MCM-41 silica from solutions with pH 7.0, whereas drug adsorption at pH 5.0 can be described by Freundlich model. The results obtained for doxorubicin adsorption kinetics and equilibrium on MCM-41 surface can be useful for comparative analysis of chemically modified silicas effectiveness.

References

1. Perry M.C. The Chemotherapy Source Book, 2nd edn. (Baltimore: Williams@Wilkins, 1996).

2. Bally M.B., Nayar R., Masin D., Cullis P.R., Mayer L.D. Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemotherapy and Pharmacology. 1990. 27(1): 13. https://doi.org/10.1007/BF00689270

3. Sumeet G., Swati M. Doxorubicin Induced Cardiotoxicity: The Spice Retreat. (Saarbruecken: Lambert Academic Publishing, 2014).

4. Roik N.V., Belyakova L.A. Cyclodextrin based drug stabilizing system. J. Mol. Struct. 2011. 987(13): 225.

5. Lee C.-H., Cheng S.-H., Huang I.-P., Souris J.S., Yang C.-S., Mou C.-Y., Lo L. W. Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics. Angew. Chem. 2010. 122(44): 8390. https://doi.org/10.1002/ange.201002639

6. Meng H., Xue M., Xia T., Zhao, Y.-L., Tamanoi, F., Stoddart, J.F., Zink,J.I., Nel A.E. Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. J. Am. Chem. Soc. 2010. 132(36): 12690. https://doi.org/10.1021/ja104501a

7. Gao Y., Chen Y., Ji X., He X., Yin Q., Zhang Z., Shi J., Li Y. Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles. Am. Chem. Sci. 2011. 5(12): 9788. https://doi.org/10.1021/nn2033105

8. Knezevic N.Z., Trewyn B.G., Lin V.S.-Y. Light- and pH-responsive release of doxorubicin from a mesoporous silica based nanocarrier. Chem. Eur. J. 2011. 17(12): 3338. https://doi.org/10.1002/chem.201002960

9. Roik N.V., Belyakova L.A. Interaction of supramolecular centers of silica surface with aromatic amino acids. J. Coll. Interf. Sci. 2011. 362(1): 172. https://doi.org/10.1016/j.jcis.2011.05.085

10. Zhang X., Clime L., Roberge H., Normandin F., Yahia L.H., Sacher E., Veres T. pH-Triggered doxorubicin delivery based on hollow nanoporous silica nanoparticles with free-standing superparamagnetic Fe3O4 cores. J. Phys. Chem. C. 2011. 115(5): 1436. https://doi.org/10.1021/jp1075498

11. Gu J., Su S., Zhu M., Li Y., Zhao W., Duan Y., Shi J. Targeted doxorubicin delivery to liver cancer cells by PEGylated mesoporous silica nanoparticles with a pH-dependent release proﬁle. Micropor. Mesopor. Mater. 2012. 161: 160. https://doi.org/10.1016/j.micromeso.2012.05.035

12. Chen Y., Yang W., Chang B., Hu H., Fang X., Sha X. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation. Europ. J. Pharm. Biopharm. 2013. 85(3): 406. https://doi.org/10.1016/j.ejpb.2013.06.015

13. Hu X., Hao X., Wu Y., Zhang J., Zhang X., Wang P.C., Zou G., Liang X. J. Multifunctional hybrid silica nanoparticles for controlled doxorubicin loading and release with thermal and pH dual response. J. Mater. Chem. B. 2013. 1: 1109. https://doi.org/10.1039/c2tb00223j

14. Mishra A.K., Pandey H., Agarwal V., Ramteke P.W., Pandey A.C. Nanoengineered mesoporous silica nanoparticles for smart delivery of doxorubicin. J. Nanopart. Res. 2014. 16: 2515. https://doi.org/10.1007/s11051-014-2515-y

15. Lee C.-H., Cheng S.-H., Huang I.-P., Souris J.S., Yang C.-S., Mou C.-Y., Lo L. W. Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics. Angew. Chem. 2010. 122: 8390. https://doi.org/10.1002/ange.201002639

16. Meng H., Xue M., Xia T., Zhao Y.-L., Tamanoi F., Stoddart J.F., Zink J.I., Nel A.E. Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. J. Am. Chem. Soc. 2010. 132: 12690. https://doi.org/10.1021/ja104501a

17. Knezevic N.Z., Trewyn B.G., Lin V.S.-Y. Light- and pH-responsive release of doxorubicin from a mesoporous silica based nanocarrier. Chem. Eur. J. 2011. 17: 3338. https://doi.org/10.1002/chem.201002960

18. Lee J.E., Lee D.J., Lee N., Kim B.H., Choi S.H., Hyeon T. Multifunctional mesoporous silica nanocomposite nanoparticles for pH controlled drug release and dual modal imaging. J. Mater. Chem. 2011. 21: 16869. https://doi.org/10.1039/c1jm11869b

19. Yuan L., Tang Q., Yang D., Zhang J.Z., Zhang F., Hu J. Preparation of pH-responsive mesoporous silica nanoparticles and their application in controlled drug delivery. J. Phys. Chem. C. 2011. 115: 9926. https://doi.org/10.1021/jp201053d

20. Gu J., Su S., Zhu M., Li Y., Zhao W., Duan Y., Shi J. Targeted doxorubicin delivery to liver cancer cells by PEGylated mesoporous silica nanoparticles with a pH-dependent release proﬁle. Micropor. Mesopor. Mater. 2012. 161: 160. https://doi.org/10.1016/j.micromeso.2012.05.035

21. Hu X., Hao X., Wu Y., Zhang J., Zhang X., Wang P.C., Zou G., Liang X. J. Multifunctional hybrid silica nanoparticles for controlled doxorubicin loading and release with thermal and pH dual response. J. Mater. Chem. B. 2013. 1: 1109. https://doi.org/10.1039/c2tb00223j

22. Knezevic N.Z., Ruiz-Hernandez E., Hennink W.E., Vallet-Regi M. Magnetic mesoporous silica-based core/shell nanoparticles for biomedical applications. RSC Adv. 2013. 3: 9584. https://doi.org/10.1039/c3ra23127e

23. Kim M.S., Jeon J.B., Chang J.Y. Selectively functionalized mesoporous silica particles with the PEGylated outer surface and the doxorubicin-grafted inner surface: improvement of loading content and solubility. Micropor. Mesopor. Mater. 2013. 172: 118. https://doi.org/10.1016/j.micromeso.2013.01.028

24. Roik N.V., Belyakova L.A. Sol-gel synthesis of MCM-41 silicas and selective vapor-phase modification of their surface. J. Solid State Chem. 2013. 207: 194. https://doi.org/10.1016/j.jssc.2013.09.027

25. Roik N.V., Belyakova L.A. Chemical design of pH-sensitive nanovalves on outer surface of mesoporous silicas for controlled storage and release of aromatic amino acid. J. Solid State Chem. 2014. 215: 284. https://doi.org/10.1016/j.jssc.2014.04.018

26. Florey K., ed. Analytical Profiles of Drug Substances. V. 9 (New York: Academic Press Inc., 1980).

27. Gritti F., Guiochon G. New thermodynamically consistent competitive adsorption isotherm in RPLC. J. Coll. Int. Sci. 2003. 264(1): 43. https://doi.org/10.1016/S0021-9797(03)00332-1

28. Ebadi A., Mohammadzadeh J.S.S., Khudiev A. What is correct form of BET isotherm for modeling liquid phase adsorption. Adsorption. 2009. 15(1): 65.https://doi.org/10.1007/s10450-009-9151-3